Dyslipidemia and its relationship with antiphospholipid antibodies in APS patients in North Kerala

Sadanand, Shajit; Paul, Binoy J; Thachil, Emil J; Meletath, Rejadheesh

doi:10.5152/eurjrheum.2016.16041

Cited by 8 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those that are available are limited in sample size and population. Sadanand and colleagues evaluated associations between antiphospholipid antibodies and dyslipidemia in patients with antiphospholipid antibody syndrome and found that abnormal lipid values were statistically associated with anticardiolipin IgM but not IgG concentration [17]. Turkoglu found that Chlamydia pneumoniae IgG and serum lipids concentrations were elevated together in patients with acute coronary artery diseases [18].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of alterations in serum immunoglobulin concentrations in components of metabolic syndrome, obesity, diabetes, and dyslipidemia

Lin

Bridgeman

Brunetti

2019

BMC Cardiovasc Disord

View full text Add to dashboard Cite

PurposeSerum immunoglobulins (Igs) play a critical role in modulating the immune response by neutralizing pathogens, although little is known about the effect of Igs in development of atherosclerotic cardiovascular disease (ASCVD). Elevated serum Immunoglobulin A (IgA) concentrations have been identified in previous studies in populations with obesity and hypertriglyceridemia, whereas variable concentrations of Immunoglobulin M (IgM) have been observed in the setting of dyslipidemia.MethodsIn this cross-sectional study, investigators examined the association of serum Ig concentrations with components of metabolic syndrome, including obesity, diabetes, and dyslipidemia. All consecutive adult patients aged 18 years or older discharged from two academic teaching hospitals with serum Immunoglobulin G (IgG) concentration measured during their admission were evaluated, with a total of 1809 individuals included and stratified into two groups: those with and those without dyslipidemia.ResultsMean IgG concentration in individuals with and without dyslipidemia was 997 ± 485 mg/dL and 1144 ± 677 mg/dL, respectively (P < 0.0001). After controlling for confounders in the generalized linear model (GLM), the least square mean IgG concentration in individuals with and without dyslipidemia was 1095 and 1239 mg/dL, respectively (P < 0.0001). The mean IgA and IgM concentrations were not significantly different in individuals with and without dyslipidemia both before and after adjusting covariates. After controlling for confounding variables, all three serum Ig concentrations were not significantly different in individuals with and without diabetes.ConclusionDyslipidemia was associated with a lower mean serum IgG concentration. No association with any serum Ig was indentified in individuals with diabetes. Exploration of the association between alterations in serum Igs and metabolic syndrome and the role of alterations of Ig concentrations in disease progression represents an important step in identification of appropriate targeted treatment options for reducing cardiovascular risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of alterations in serum immunoglobulin concentrations in components of metabolic syndrome, obesity, diabetes, and dyslipidemia

Lin

Bridgeman

Brunetti

2019

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

“…As serum lipoproteins contain phospholipids, they may become a potential target for antiphospholipid antibodies. 21 We should point out that this conclusion mentioned above is based on the studies from APS patients. Further fundamental research is needed to clarify whether or not anti-MDA5 antibodies is related to lipid levels.…”

Section: Discussionmentioning

confidence: 90%

Clinical Characteristics of Lipid Metabolism in Untreated Patients with Anti-MDA5 Antibody-Positive

Huang¹,

Ren²,

Luo³

et al. 2021

IJGM

View full text Add to dashboard Cite

Objective Clinical characterization of lipid metabolism in untreated patients with anti-melanoma differentiation-associated gene 5 antibodies-positive (anti-MDA5 + ). Methods Body-mass index (BMI), autoantibodies, lipid levels, and serum ferritin levels in 57 anti-MDA5 + patients were determined in the Department of Rheumatology and Immunology of the Second Affiliated Hospital of Chongqing Medical University. Results Plasma high-density lipoprotein (HDL) and apolipoprotein A1 (ApoA1) levels were significantly lower in deceased group than in the survival group (P < 0.05). Plasma levels of HDL and ApoA1 were significantly lower in patients who were simultaneously anti-MDA5 + and anti-Ro-52 + than in patients who were anti-MDA5 + alone (P < 0.05). Plasma levels of total cholesterol, low-density lipoprotein, HDL, and ApoA1 were significantly decreased in patients with high levels of serum ferritin compared with patients with low levels (P < 0.05). There were no significant differences in blood lipid levels between patients grouped according to BMI. Conclusion 1) HDL and ApoA1 levels are important indicators of poor prognosis in anti-MDA5 + patients; 2) Dysregulated lipid metabolism in anti-MDA5 + patients is closely associated with anti-Ro-52 antibody and ferritin levels but independent of BMI; 3) HDL involvement in inflammation and immune regulation merits close attention by rheumatologists.

show abstract

“…The most general dyslipidemia case in the study population is TG level > 150 mg/dL(51.9%), while LDL > 150 mg/dL(40.2%) takes second place. Statistics show a significant correlation among anti-β2G IgG levels, HDL and LDL level, and aCL IgM level and LDL [ 14 ]. Antibodies to oxidized LDLs and cardiolipins were associated with thrombosis and atherosclerotic complications in patients with SLE as early as 1993 [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

“…APS-related comorbidities in the study population that were considered included diabetes mellitus [ 10 ] (ICD-9-CM 250), hypertension [ 11 – 13 ] (ICD-9-CM 401–405), hyperlipidemia [ 14 ] (ICD-9-CM 272), stroke [ 10 ](ICD-9-CM 430–438), heart failure [ 15 ] (ICD-9-CM 428), atrial fibrillation [ 16 ] (ICD-9-CM 427.32), myocardial infarction [ 17 ] (ICD-9-CM 410–410.9, 412), peripheral arterial occlusive disease [ 10 ] (PAOD; ICD-9-CM 440–444), chronic kidney disease [ 13 ] (ICD-9-CM 580–589), chronic obstructive pulmonary disease [ 18 ](COPD; ICD-9-CM 490–496), deep vein thrombosis [ 10 ] (ICD-9-CM 451.1, 451.2, 451.8, and 453), pulmonary embolism [ 10 ] (ICD-9-CM 415.1), systemic lupus erythematosus [ 10 ] (SLE; ICD-9-CM 710.0), rheumatoid arthritis [ 19 ] (ICD-9-CM 714), systemic sclerosis [ 20 ] (ICD-9-CM 710.1), Sjogren’s syndrome [ 21 ] (ICD-9-CM 710.2), and polymyositis [ 22 ] (ICD-9-CM 710.4).…”

Section: Methodsmentioning

confidence: 99%

The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study

et al. 2022

View full text Add to dashboard Cite

Background This study aims to provide 14-year nationwide epidemiology data to evaluate the incidence ratio of APS in Taiwan and the condition of comorbidities by analyzing the National Health Insurance Research Database. Methods Nineteen thousand one hundred sixty-three patients newly diagnosed as having APS during the 2000–2013 period and 76,652 controls (with similar distributions of age and sex) were analyzed. Results The incidence of APS increased from 4.87 to 6.49 per 10,000 person-years in the Taiwan population during 2000–2013. The incidence of APS increased with age after 20 years old, especially in the female population, and it rose rapidly after age over 60 years old. In addition, APS cohorts presented a higher proportion of diabetes mellitus, hypertension, hyperlipidemia, stroke, heart failure, atrial fibrillation, myocardial infarction, PAOD, chronic kidney disease, COPD, deep vein thrombosis, pulmonary embolism, SLE, rheumatoid arthritis, Sjogren’s syndrome, and polymyositis. Conclusions Our study indicated an increasing trend in APS incidence among the Taiwanese population and a relationship between APS and potential comorbidities. This large national study found that the APS risk is heavily influenced by sex and age. Thus, the distinctive sex and age patterns might be constructive given exploring potential causal mechanisms. Furthermore, our findings indicate that clinicians should have a heightened awareness of the probability of APS, especially in women in certain age groups presenting with symptoms of APS.

show abstract

Dyslipidemia and its relationship with antiphospholipid antibodies in APS patients in North Kerala

Cited by 8 publications

References 11 publications

Evaluation of alterations in serum immunoglobulin concentrations in components of metabolic syndrome, obesity, diabetes, and dyslipidemia

Evaluation of alterations in serum immunoglobulin concentrations in components of metabolic syndrome, obesity, diabetes, and dyslipidemia

Clinical Characteristics of Lipid Metabolism in Untreated Patients with Anti-MDA5 Antibody-Positive

The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study

Contact Info

Product

Resources

About